09.25.26 -- Evaluating The Levers Driving Productivity In Bioprocessing

Ten hard-won lessons from seasoned biopharma professionals cover the foundational habits, verification steps, and process controls that protect batch integrity and prevent costly deviations.

Novel bispecific antibody engineering overcomes assembly and manufacturability challenges, enabling scalable production while preserving therapeutic function, stability, purity, and product quality.

Accelerate cell line development with a host engineered for high expression, streamlined clone selection, flexible gene integration, and scalable industrial performance.

Biotechnology moves quickly, and successful innovation depends on more than breakthrough science. See how adaptable strategies can help teams connect emerging tools and manage uncertainty.

Delve into the complexities of scaling decisions to gain insights from developers and a CDMO. Learn about their mutual interest in achieving successful scale-up and strategies for avoiding pitfalls.

Structurally similar impurities can be difficult to separate in GLP-1 therapeutics. Find out how column chemistry influences selectivity and supports more confident profiling for peptide-based drugs.

Small changes in mobile phase, temperature, and column chemistry can affect the detection of GLP-1 peptide impurities. Observe which conditions improve resolution for challenging peptide analyses.

The ISABEL trap, which deploys interferometric scattering as a highly sensitive, fluorophore-label-free detection scheme, enables precise interpretation of the actions of complex biomolecular nanoparticles.

Flexible development and manufacturing are essential for complex biologics. Explore scalable processes, advanced cell line strategies, and partnership models that move programs efficiently.

Discover how structured design-of-experiment approaches can optimize charge variants and glycosylation to enhance biologics quality and therapeutic performance.

Gain insight into how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.

Examine how AI, QbD, and digital transformation are reshaping manufacturing to accelerate scale-up, reduce defects, and optimize batch release for faster, more resilient operations.

New technologies for the encapsulation of nucleic acids, such as FDmiX, can potentially overcome limitations of currently available standard mixing technologies.

Stricter regulatory expectations for AAV therapies demand robust control of residual transfection reagents, comprehensive documentation, and proactive quality strategies to avoid costly delays.

Take a look at the intricacies of Impingement Jets Mixing (IJM) technology and its pivotal role in the scalable and reproducible production of Lipid Nanoparticles (LNPs) for drug delivery.

Uncover how early stable CHO expression data reveals manufacturability issues in complex antibodies that transient screening misses, with case studies showing how this changes lead selection.

Learn how rational design and optimized feed strategies enable high-titer protein expression and full incorporation of non-canonical amino acids at scale, overcoming common toxicity and yield bottlenecks.

Explore freeze and thaw technology that is being used to prevent alterations in the drug substance through the minimization of protein aggregation.

Review how modular strategies, global coordination, and data-driven decisions help maintain continuity, compliance, and speed amid constant uncertainty.

Drug manufacturers seek packaging that maintains integrity during processing and freezing, scales up to larger volumes easily, and remains robust throughout the temperature-controlled supply chain.